Silo Pharma Targets TBI Market with Ibogaine-Based Patent Filing

Event summary

  • Silo Pharma filed a provisional patent for ibogaine-based therapeutics targeting traumatic brain injury (TBI) and associated neuropsychiatric conditions.
  • The patent application, titled 'Compositions and Methods for Treating Traumatic Brain Injuries and/or Disorders Associated therewith with Ibogaine,' was submitted to the USPTO on May 7, 2026.
  • The TBI therapeutics market is projected to reach $6 billion by 2032, growing at a CAGR of 6.0% between 2025 and 2032.
  • No FDA-approved therapies currently address the structural or regenerative aspects of TBI.

The big picture

Silo Pharma's patent filing aligns with federal actions to accelerate mental health innovation using psychedelic medicines. The company is targeting an unmet need in the TBI market, where no FDA-approved therapies address structural or regenerative aspects. The TBI therapeutics market is projected to reach $6 billion by 2032, driven by increasing incidence of brain injuries and rapid advancements in treatment options.

What we're watching

Regulatory Tailwinds
How the FDA's Breakthrough Therapy designation for psychedelic drugs will accelerate Silo Pharma's development timeline.
Clinical Validation
Whether ibogaine-based protocols can sustain measurable structural brain improvements in TBI patients.
Market Penetration
The pace at which Silo Pharma can capture share in the $6 billion TBI therapeutics market.